<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330508</url>
  </required_header>
  <id_info>
    <org_study_id>IEC-D3/2018-866</org_study_id>
    <nct_id>NCT04330508</nct_id>
  </id_info>
  <brief_title>Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial</brief_title>
  <official_title>Effects of Direct-acting Antiviral Agents on Cognitive Function, and Depression in Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Minimal hepatic encephalopathy (MHE) is an important clinical variant of hepatic
      encephalopathy (HE), which occurs in up to 60-70% of patients with cirrhosis. The condition
      comprises a cognitive impairment, observed in patients with cirrhosis who have no clinical
      evidence of overt hepatic encephalopathy (OHE). It is associated with an increased incidence
      of road traffic accidents, reduced quality of life and it affects the ability to perform
      tasks of daily living. Successful treatment of hepatitis C has been reported to be associated
      with 62-84% reduction in all-cause mortality (deaths), 68-79% reduction in risk of HCC and
      90% reduction in risk of liver transplantation. In addition, studies have shown that viral
      eradication may improve cognition when given interferon based regimens for HCV. With the
      available of safe, efficacious, all oral regimens for HCV, we plan to prospectively analyse
      the change in mood, depression and cognitive function in response to DAA therapy, in relation
      to outcomes of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigations will be performed according to the Declaration of Helsinki and approval of the
      enrolment as well as the usage of patient blood samples for research purpose will be obtained
      from the institutional ethics committee, and written informed consent will be obtained from
      all patients.The primary analysis upon which the sample size consideration was based involved
      the comparison of the SVR subgroup and the subgroup of patients without SVR. For the sample
      size calculation, we a two-factorial design (time course × SVR) with the use of a two-way
      analysis of variance (ANOVA) analysis, a significance level of 5% and a statistical power of
      at least 80% to detect a medium effect size (d = 0.5) and thus to show a significant group
      difference. Based on this background, the optimal sample size is calculated to be a total of
      102 subjects. To consider asymmetric subgroups and to allow for a moderate dropout rate and
      additional calculations (secondary study objectives), we aim to include a total of at least
      150 study participants in each group with 25 healthy volunteers as controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive performance</measure>
    <time_frame>Day 0</time_frame>
    <description>Computerized battery (Reaction times, simple and choice, visual memory, Number connection test, and Inhibitory Control Test)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive performance</measure>
    <time_frame>90 days after treatment completion</time_frame>
    <description>Computerized battery (Reaction times, simple and choice, visual memory, Number connection test, and Inhibitory Control Test)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive performance using conventional tests</measure>
    <time_frame>Day 0</time_frame>
    <description>Psychometric hepatic encephalopathy score (PHES), Indian Version.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive performance using conventional tests</measure>
    <time_frame>90 days after treatment completion</time_frame>
    <description>Psychometric hepatic encephalopathy score (PHES), Indian Version.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQOL by SF-36</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQOL by SF-36</measure>
    <time_frame>90 days after treatment completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression Scale</measure>
    <time_frame>Day 0</time_frame>
    <description>Beck's Depression Inventory (BDI) Generalized anxiety disorder (GAD 7 score) Psychometric hepatic encephalopathy Score (PHES) Montreal Cognitive assessment Score (MoCA Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Scale</measure>
    <time_frame>90 days after treatment completion</time_frame>
    <description>Beck's Depression Inventory (BDI) Generalized anxiety disorder (GAD 7 score) Psychometric hepatic encephalopathy Score (PHES) Montreal Cognitive assessment Score (MoCA Score)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Depression in Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Chronic hepatitis C without Cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic hepatitis C with Cirrhosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Depression and Cognitive Tests</intervention_name>
    <description>Health Related Quality of Life, neurocognitive tests, PHES</description>
    <arm_group_label>Chronic hepatitis C with Cirrhosis</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <other_name>SF36</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Chronic hepatitis C Infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years and chronic HCV infection.

          -  Group A: Patients with hepatitis C (Non-cirrhotic) [n= 150]

          -  Group B: Patients with hepatitis C related compensated-cirrhosis [n= 150]

          -  Group C: Healthy volunteers [n= 25]

        Exclusion Criteria:

          -  Current overt hepatic encephalopathy or during the last 1 month

          -  TIPS (transjugular intra- hepatic porto-systemic shunt)

          -  elective surgery planned within the next 8 weeks

          -  unable to give informed consent

          -  HIV infection

          -  chronic respiratory insufficiency

          -  current infection and receiving antibiotics

          -  renal failure (serum creatinine ≥ 1.5 mg/l)

          -  hepatocellular carcinoma,

          -  patient with other neurological disease

          -  intake of sedatives, antidepressants, benzodiazepines, or benzodiazepines-antagonists
             (flumazenil, neuromuscular blocking agents)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhumita Premkumar, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Madhumita Premkumar, DM</last_name>
    <phone>01722756344</phone>
    <email>drmadhumitap@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhumita PREMKUMAR</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Butterworth RF. Editorial: rifaximin and minimal hepatic encephalopathy. Am J Gastroenterol. 2011 Feb;106(2):317-8. doi: 10.1038/ajg.2010.460.</citation>
    <PMID>21301455</PMID>
  </reference>
  <reference>
    <citation>Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007 Feb;25 Suppl 1:3-9. Review.</citation>
    <PMID>17295846</PMID>
  </reference>
  <reference>
    <citation>Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis. 2004 Dec;19(3-4):253-67. Review.</citation>
    <PMID>15554421</PMID>
  </reference>
  <reference>
    <citation>Kircheis G, Knoche A, Hilger N, Manhart F, Schnitzler A, Schulze H, Häussinger D. Hepatic encephalopathy and fitness to drive. Gastroenterology. 2009 Nov;137(5):1706-15.e1-9. doi: 10.1053/j.gastro.2009.08.003. Epub 2009 Aug 15.</citation>
    <PMID>19686744</PMID>
  </reference>
  <reference>
    <citation>Ortiz M, Córdoba J, Jacas C, Flavià M, Esteban R, Guardia J. Neuropsychological abnormalities in cirrhosis include learning impairment. J Hepatol. 2006 Jan;44(1):104-10. Epub 2005 Jul 11.</citation>
    <PMID>16169117</PMID>
  </reference>
  <reference>
    <citation>Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, Saeian K, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Luketic V, White MB, Sanyal AJ. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010 Jun;138(7):2332-40. doi: 10.1053/j.gastro.2010.02.015. Epub 2010 Feb 20.</citation>
    <PMID>20178797</PMID>
  </reference>
  <reference>
    <citation>Bajaj JS, Saeian K, Schubert CM, Hafeezullah M, Franco J, Varma RR, Gibson DP, Hoffmann RG, Stravitz RT, Heuman DM, Sterling RK, Shiffman M, Topaz A, Boyett S, Bell D, Sanyal AJ. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009 Oct;50(4):1175-83. doi: 10.1002/hep.23128.</citation>
    <PMID>19670416</PMID>
  </reference>
  <reference>
    <citation>Conn HO. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis. 1977 Jun;22(6):541-50.</citation>
    <PMID>868833</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Madhumita Premkumar</investigator_full_name>
    <investigator_title>Assistant professor, Department of heaptology</investigator_title>
  </responsible_party>
  <keyword>Neurocognition, Minimal hepatic encephalopathy, Direct antivirals, DAAs, Chronic hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

